ATE200864T1 - Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid - Google Patents

Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid

Info

Publication number
ATE200864T1
ATE200864T1 AT97937651T AT97937651T ATE200864T1 AT E200864 T1 ATE200864 T1 AT E200864T1 AT 97937651 T AT97937651 T AT 97937651T AT 97937651 T AT97937651 T AT 97937651T AT E200864 T1 ATE200864 T1 AT E200864T1
Authority
AT
Austria
Prior art keywords
controlled release
release tablet
alfuzosine
hydrochloride
alfuzosine hydrochloride
Prior art date
Application number
AT97937651T
Other languages
English (en)
Inventor
Lauretta Maggi
Ubaldo Conte
Pascal Grenier
Guy Vergnault
Alain Dufour
Francois Xavier Jarreau
Clemence Rauch-Desanti
Original Assignee
Sanofi Synthelabo
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE200864(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Sanofi Synthelabo, Jagotec Ag filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE200864T1 publication Critical patent/ATE200864T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
AT97937651T 1996-08-29 1997-08-22 Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid ATE200864T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr) 1996-08-29 1997-08-22 Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (1)

Publication Number Publication Date
ATE200864T1 true ATE200864T1 (de) 2001-05-15

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97937651T ATE200864T1 (de) 1996-08-29 1997-08-22 Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid

Country Status (37)

Country Link
US (1) US6149940A (de)
EP (1) EP0938318B1 (de)
JP (1) JP3797388B2 (de)
KR (1) KR100364328B1 (de)
CN (2) CN1155382C (de)
AP (1) AP1107A (de)
AR (1) AR009312A1 (de)
AT (1) ATE200864T1 (de)
AU (1) AU724490B2 (de)
BG (1) BG63768B1 (de)
BR (1) BR9713237B1 (de)
CA (1) CA2264250C (de)
CO (1) CO4920217A1 (de)
CY (1) CY2284B1 (de)
CZ (1) CZ295066B6 (de)
DE (1) DE69704712T2 (de)
DK (1) DK0938318T3 (de)
EE (1) EE03855B1 (de)
ES (1) ES2159400T3 (de)
GR (1) GR3036291T3 (de)
HK (1) HK1020875A1 (de)
HU (1) HU228007B1 (de)
IL (1) IL128146A (de)
IS (1) IS2091B (de)
MX (1) MXPA99001958A (de)
NO (1) NO326206B1 (de)
NZ (1) NZ334018A (de)
OA (1) OA10983A (de)
PL (1) PL191546B1 (de)
PT (1) PT938318E (de)
RU (1) RU2183459C2 (de)
SI (1) SI0938318T1 (de)
SK (1) SK284388B6 (de)
TR (1) TR199900289T2 (de)
TW (1) TW522023B (de)
UA (1) UA69374C2 (de)
WO (1) WO1998008515A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
ATE340563T1 (de) * 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
MXPA05004338A (es) * 2002-10-22 2005-06-22 Ranbaxy Lab Ltd Composiciones de liberacion sostenida que contienen alfuzosin.
AU2005266459A1 (en) * 2004-07-29 2006-02-02 Sanofi-Aventis Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
EP2392258B1 (de) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-Informatiksystem
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
EP1976488A4 (de) * 2006-01-12 2010-02-10 Wockhardt Ltd Zusammensetzungen aus alfuzosin mit verzögerter freisetzung
CN105468895A (zh) 2006-05-02 2016-04-06 普罗透斯数字保健公司 患者定制的治疗方案
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
JPWO2008041553A1 (ja) 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
EP2083680B1 (de) 2006-10-25 2016-08-10 Proteus Digital Health, Inc. Einnehmbarer identifikator mit kontrollierer aktivierung
EP2069004A4 (de) 2006-11-20 2014-07-09 Proteus Digital Health Inc Persönliche gesundheitssignalempfänger mit aktiver signalverarbeitung
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
JPWO2008084698A1 (ja) 2006-12-28 2010-04-30 アステラス製薬株式会社 タクロリムス徐放性医薬組成物
MY165532A (en) 2007-02-01 2018-04-02 Proteus Digital Health Inc Ingestible event marker systems
CA2676280C (en) 2007-02-14 2018-05-22 Proteus Biomedical, Inc. In-body power source having high surface area electrode
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
EP2124725A1 (de) 2007-03-09 2009-12-02 Proteus Biomedical, Inc. Körperintegrierte vorrichtung mit multidirektionalem sender
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
DK2192946T3 (da) 2007-09-25 2022-11-21 Otsuka Pharma Co Ltd Kropsintern anordning med virtuel dipol signalforstærkning
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MY161533A (en) 2008-03-05 2017-04-28 Proteus Digital Health Inc Multi-mode communication ingestible event markers and systems, and methods of using the same
WO2009149029A2 (en) * 2008-06-04 2009-12-10 The Procter & Gamble Company Denture adhesive compositions and methods
SG195535A1 (en) 2008-07-08 2013-12-30 Proteus Digital Health Inc Ingestible event marker data framework
KR101214453B1 (ko) 2008-08-13 2012-12-24 프로테우스 디지털 헬스, 인코포레이티드 복용 가능한 회로
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
AU2010203625A1 (en) 2009-01-06 2011-07-21 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
TWI602561B (zh) 2009-01-06 2017-10-21 波提亞斯數位康健公司 醫藥劑量傳送系統
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
WO2010111403A2 (en) 2009-03-25 2010-09-30 Proteus Biomedical, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
CN102458236B (zh) 2009-04-28 2016-01-27 普罗秋斯数字健康公司 高可靠性的可摄入事件标记器及其使用方法
WO2010132331A2 (en) 2009-05-12 2010-11-18 Proteus Biomedical, Inc. Ingestible event markers comprising an ingestible component
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
BR112012022646A2 (pt) 2010-03-10 2016-08-23 Procter & Gamble composições adesivas para dentaduras
PL2554168T3 (pl) 2010-03-29 2018-05-30 Astellas Pharma Inc. Kompozycja farmaceutyczna do kontrolowanego uwalniania
WO2011127252A2 (en) 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
EP2555756B1 (de) * 2010-04-07 2018-08-22 Lupin Limited Pharmazeutische retard-zusammensetzungen aus tapentadol
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス, インコーポレイテッド 医薬品を有する摂取可能なデバイス
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
BR112014001397A2 (pt) 2011-07-21 2017-02-21 Proteus Biomedical Inc dispositivo, sistema e método de comunicação móvel
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
WO2014018454A1 (en) 2012-07-23 2014-01-30 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
JP5869736B2 (ja) 2012-10-18 2016-02-24 プロテウス デジタル ヘルス, インコーポレイテッド 通信デバイス用の電源において電力消失およびブロードキャスト電力を適応的に最適化するための装置、システム、および方法
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス, インコーポレイテッド 金属検出器装置、システム、および方法
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス, インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
KR20210018961A (ko) 2016-07-22 2021-02-18 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 이벤트 마커의 전자기 감지 및 검출
IL265827B2 (en) 2016-10-26 2023-03-01 Proteus Digital Health Inc Methods for producing capsules with ingestible event markers
CN114209668B (zh) * 2022-01-13 2023-01-31 山东新时代药业有限公司 一种盐酸阿夫唑嗪缓释制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Also Published As

Publication number Publication date
BR9713237B1 (pt) 2009-01-13
EP0938318A1 (de) 1999-09-01
MXPA99001958A (es) 2005-09-08
CN100335057C (zh) 2007-09-05
CY2284B1 (en) 2003-07-04
AP1107A (en) 2002-09-20
CN1543954A (zh) 2004-11-10
SK284388B6 (sk) 2005-02-04
US6149940A (en) 2000-11-21
AU724490B2 (en) 2000-09-21
SK27099A3 (en) 1999-12-10
NO990944D0 (no) 1999-02-26
CO4920217A1 (es) 2000-05-29
RU2183459C2 (ru) 2002-06-20
CA2264250A1 (en) 1998-03-05
AU4020197A (en) 1998-03-19
PL331862A1 (en) 1999-08-16
TW522023B (en) 2003-03-01
CZ295066B6 (cs) 2005-05-18
SI0938318T1 (en) 2001-12-31
CN1228700A (zh) 1999-09-15
AP9901470A0 (en) 1999-03-31
NZ334018A (en) 1999-06-29
HU228007B1 (en) 2012-08-28
KR20000035929A (ko) 2000-06-26
CN1155382C (zh) 2004-06-30
DE69704712D1 (de) 2001-06-07
CA2264250C (en) 2005-07-05
TR199900289T2 (xx) 2000-12-21
JP2000514462A (ja) 2000-10-31
WO1998008515A1 (fr) 1998-03-05
ES2159400T3 (es) 2001-10-01
EE9900090A (et) 1999-10-15
OA10983A (fr) 2003-03-04
KR100364328B1 (ko) 2002-12-26
UA69374C2 (uk) 2004-09-15
IL128146A0 (en) 1999-11-30
PL191546B1 (pl) 2006-06-30
EP0938318B1 (de) 2001-05-02
CZ65599A3 (cs) 1999-06-16
IS4964A (is) 1999-01-29
BG103138A (en) 1999-09-30
HUP9903428A3 (en) 2000-04-28
GR3036291T3 (en) 2001-10-31
DK0938318T3 (da) 2001-08-20
HK1020875A1 (en) 2000-05-26
HUP9903428A2 (hu) 2000-02-28
IL128146A (en) 2001-01-11
IS2091B (is) 2006-03-15
DE69704712T2 (de) 2001-11-29
NO326206B1 (no) 2008-10-20
BR9713237A (pt) 2000-04-04
AR009312A1 (es) 2000-04-12
EE03855B1 (et) 2002-10-15
BG63768B1 (bg) 2002-12-29
PT938318E (pt) 2001-10-30
NO990944L (no) 1999-04-27
JP3797388B2 (ja) 2006-07-19

Similar Documents

Publication Publication Date Title
ATE200864T1 (de) Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid
DE69732113D1 (de) Schnelllösliche tablette enthaltend galanthaminhydrobromid
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DE69625189D1 (de) Tablette mit gesteuerter freisetzung
DK0811006T3 (da) Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse
NO980240L (no) Paroxetin-kontrollert frigjörings-blandinger
DK0699436T4 (da) Præparat med reguleret frigivelse
FI943168A (fi) Opioidiformulaatioita, joissa on pitkitetty säädelty vapautuminen
DE59707194D1 (de) Direkttablettierhilfsmittel
ATE239481T1 (de) Filmueberzogene tabletten von oxacarbazepin
DE69128569T2 (de) Tablette mit verzögerter Wirkstoffabgabe
ATE367150T1 (de) Arzneimittel
ATE240720T1 (de) Paracetamol enthaltende schlickbare tablette
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
BR9708528A (pt) Terapia com libertação uniforme de droga
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
ATE300297T1 (de) Umhüllte tablette enthaltend trimebutin maleat
NO983090D0 (no) Terapeutiske forbindelser
FI955605A0 (fi) Aryloivia lääkkeitä
DE29813269U1 (de) Tablette
NO992244D0 (no) AIDS-legemiddel
ZA977766B (en) Tablet with controlled release of alfuzosin hydrochloride.
DE29517296U1 (de) Medikamententimer
DE69617790D1 (de) Synchronisierter Zeitschalter
UA1246S (uk) Таблетка фармацевтична

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification